Latest research on Copaxone

Glatiramer acetate consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000-9,000 daltons. It is an immunomodulator, licensed in much of the world for reduced frequency of relapses in relapsing-remitting multiple sclerosis

Copaxone side effects

This is consistent with literature reports showing that Copaxone positively impacts CD16+ monocytes, [42] and is particularly concerning from a safety perspective because the CD16dim monocytes favored by generic are known to play a different biological role. [source, 2014]
Furthermore, because codelivery of both antigen and a secondary “context” signal through separate homopolymers was effective at treating EAE, this therapeutic paradigm may ultimately be adaptable as a supplemental additive formulation to current antigen only therapeutics such as Copaxone (R) (myelin antigen derivative) and therapeutics such as Tysabri (R) (surface receptor) inhibitor. [source, 2014]
Glatiramer acetate (Copaxone) is the only DMT with an FDA pregnancy “Category B” drug, meaning it did not cause harm to fetuses in animal studies. [source, 2014]
One Internet report, connected to the FDA adverse events reporting database, stated that, of 9,277 patients who reported to have side effects while taking Copaxone, 3 experienced eosinophilia (0.03%) [15]. [source, 2014]
A significant decrease in the concentration of autoAbs to full-length MBP, compared to the control group, was observed only in rats treated with p1 mSUV, p123 mSUV, and Copaxone (Fig. 5A, left panel). [source, 2013]
As interferon and Copaxone are prescribed because of their MS-specific, immunosuppressive, effect and MS is likely an autoimmune disease, it is reasonable to expect some decrease in humoral immune function among specifically treated patients, as reflected by the low anti-PLP test scores exhibited in Figure 20. [source, 2012]
Copaxone and Rebif/Avonex (IFNs) also increase NK cell cytotoxic activity (Sand et al., 2009; Vandenbark et al., 2009) and the prevalence of CD56bright NK cells, respectively. [source, 2010]